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Abstract
Thiopurine methyltransferase (Tpmt) is the primary enzyme responsible for deactivating thiopurine drugs. Thiopurine drugs
(i.e., thioguanine [TG], mercaptopurine, azathioprine) are commonly used for the treatment of cancer, organ transplant, and
autoimmune disorders. Chronic thiopurine therapy has been linked to the development of brain cancer (most commonly
astrocytomas), and Tpmt status has been associated with this risk. Therefore, we investigated whether the level of Tpmt
protein activity could predict TG-associated cytotoxicity and DNA damage in astrocytic cells. We found that TG induced
cytotoxicity in a dose-dependent manner in Tpmt
+/+, Tpmt
+/2 and Tpmt
2/2 primary mouse astrocytes and that a low Tpmt
phenotype predicted significantly higher sensitivity to TG than did a high Tpmt phenotype. We also found that TG exposure
induced significantly more DNA damage in the form of single strand breaks (SSBs) and double strand breaks (DSBs) in
primary astrocytes with low Tpmt versus high Tpmt. More interestingly, we found that Tpmt
+/2 astrocytes had the highest
degree of cytotoxicity and genotoxicity (i.e., IC50, SSBs and DSBs) after TG exposure. We then used human glioma cell lines
as model astroglial cells to represent high (T98) and low (A172) Tpmt expressers and found that A172 had the highest
degree of cytoxicity and SSBs after TG exposure. When we over-expressed Tpmt in the A172 cell line, we found that TG IC50
was significantly higher and SSB’s were significantly lower as compared to mock transfected cells. This study shows that low
Tpmt can lead to greater sensitivity to thiopurine therapy in astroglial cells. When Tpmt deactivation at the germ-line is
considered, this study also suggests that heterozygosity may be subject to the greatest genotoxic effects of thiopurine
therapy.
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Introduction
Thiopurine methyltransferase (Tpmt) is a cytoplasmic enzyme
responsible for catalyzing the S-methylation of aromatic and
heterocyclic compounds and is the primary deactivating enzyme
for thiopurine drugs [1]. Thiopurines are antimetabolite pro-drugs
that require intracellular conversion to the active metabolites to
exert their cytotoxic effects (Fig. 1) [2]. Alternatively, thiopurine
activation is in competition with deactivation pathways primarily
involving Tpmt. Tpmt has been studied extensively because of
inter-patient variability in Tpmt protein expression owing to a few
common genetic polymorphisms [3,4,5]. Deactivating polymor-
phisms in Tpmt can result in a trimodal population distribution in
enzymatic activity. Inheritance of two functional alleles results in
high protein activity (,90% of individuals), heterozygosity leads to
intermediate activity (,10% of individuals), and inheritance of
two dysfunctional alleles results in practically no protein activity
(,1% of individuals) [6,7]. Importantly, low Tpmt has been
associated with life-threatening toxicities including cancer in
patients receiving thiopurine therapy [8,9,10,11,12].
Over the past several decades, thiopurines [e.g. thioguanine
(TG), mercaptopurine, and azathioprine] have been commonly
used in the treatment of cancer, autoimmune disorders, and in
organ transplant. In each of these patient populations there have
been a number of reports of cancer development after thiopurine
therapy to include acute myeloid leukemias, lymphomas, and
cancers of the skin and brain [8,13,14,15,16,17,18,19,20,21,
22,23,24]; although, the relevance of Tpmt status is not clear.
However, in a study by Relling et al it was found that when patients
were treated with antimetabolites (i.e. mercaptopurine, metho-
trexate) and prophylactic cranial irradiation as part of their
antileukemic therapy, whether they developed a brain tumor
depended on their Tpmt status [8,24]. Patients who had a low
Tpmt phenotype were more likely to develop a brain tumor as a
late complication than those who had high Tpmt (42.9% versus
15.8% 10-year cumulative incidence, respectively) [8].
Tpmt is constitutively expressed in several tissues including
blood, kidney, liver, and brain [25,26,27,28,29]. The association
of Tpmt status with brain tumor risk after thiopurine exposure
prompts the question of whether Tpmt genotypes can predict
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29163thiopurine drug phenotypes in astroglial cells. The relevance of
Tpmt status to thiopurine-associated phenotypes in important
brain cell populations has not been studied. Indeed, the first step to
address the question of whether Tpmt plays any role in brain
cancer risk after thiopurines is to determine whether Tpmt
phenotypes in the brain are similar to those in other tissues.
Thiopurine drug-associated genotoxicity has been linked to
mutagenesis and transformative events [30,31,32]. We hypothesize
that Tpmt deficiency can lead to greater genotoxicity (i.e. DNA
damage) and cytotoxicity in astroglial cells after thiopurine
exposure. To address this hypothesis we used primary astrocytes
isolated from transgenic mice of each Tpmt genotype and
performed in vitro studies to compare thiopurine-induced cytotox-
icity and DNA damage between Tpmt genotypes. We also used
established human glioma cell lines as model astroglial cells to
validate the findings observed in primary mouse astrocytes.
Results
Characterization of Tpmt
+/+, Tpmt
+/2, and Tpmt
2/2
primary mouse astrocyte cultures
The primary mechanism of thiopurine cytoxicity is believed to be
through incorportation of TG nucleotide metabolites into DNA
[2,31,33](Fig. 1), and therefore is dependent on the rate of cell
proliferation. Hence, we first compared the doubling rates between
Tpmt
+/+, Tpmt
+/2, and Tpmt
2/2 primary astrocyte cultures.
Primary cultures were established from mouse cortices of each
Tpmt genotype and astrocyte purity was confirmed by GFAP (glial
fibrillary acid protein, an astrocyte marker) fluorescent staining
(Fig.2a).Wefoundthattherewasnosignificantdifferenceingrowth
rates between cultures of different Tpmt genotypes (Fig. 2b). The
mean doubling rates for Tpmt
+/+, Tpmt
+/2 and Tpmt
2/2 cultures
were 33.9, 34.2, and 29.6 hours, respectively (p=0.89). Next, we
measured the level of Tpmt protein activity using a well-established
radiochemical assay that measures the conversion of 6-mercapto-
purine to 6-methylmercaptopurine using [14C] S-adenosyl-L-
methionine (SAM) as a methyl donor [34]. In agreement with
previous studies comparing protein activity in hematological cells of
different Tpmt genotypes [5,29,35], protein activities in astrocytes
were significantly different and were predicted by Tpmt genotype
(Fig. 2c). Tpmt
+/+, Tpmt
+/2, and Tpmt
2/2 primary astrocytes
displayed high (7.6 unit/10
9 mg protein), intermediate (3.9 unit/
10
9 mg protein), and low (0.25 unit/10
9 mg protein) levels of protein
activity, respectively (p=0.018). Based on these data, we next
determined whether Tpmt could modulate the cytotoxic effects of
TG in primary astrocytes.
Comparison of thioguanine-associated cytotoxicity in
Tpmt
+/+, Tpmt
+/2, and Tpmt
2/2 primary astrocyte
cultures
To determine whether Tpmt could predict thiopurine cytotox-
icity in primary astrocytes, the MTT colorimetric assay was
Figure 1. Thiopurine drug metabolism pathway. Azathioprine (AZA) is a prodrug of mercaptopurine (MP). Thioguanine (TG) and MP can be
converted by hypoxanthine phosphoribosyl transferase (HPRT) to thioguanine nucleotide (TGNs) metabolites. MP can also be converted to the
methylthioinosine monophosphate (meTIMP) by thiopurine methyltransferase (Tpmt) which inhibits purine synthesis; however, thioguanine
bypasses the conversion to this metabolite. Thiopurines can be converted to inactive metabolites [i.e. methyl-mercaptopurine (meMP); methyl-
thioguanine (meTG); and methyl-thioguanine nucleotides (meTGNs)] by Tpmt. TGN metabolites are incorporated into DNA and RNA leading to cell
death. However, DNA incorporation is believed to be the primary mode of cytotoxicty.
doi:10.1371/journal.pone.0029163.g001
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Tpmt genotype. This assay measures cell viability by quantitating
the extent at which metabolically active cells can reduce
tetrazolium salt (MTT) to form purple formazan crystals.
Astrocytes were exposed to escalating concentrations of TG
(0.125, 1.25, 12.5, 25, 50, and 100 mM) for five days and then
subjected to the MTT assay. Cell viability data at each TG
concentration was used to calculate IC50 values. As expected, TG
treatment resulted in cytotoxicity in a dose dependant manner
(Figure 3a). Cell viability was significantly lower in Tpmt
+/2 and
Tpmt
2/2 cultures at four concentrations of TG (12.5, 25, 50, and
100 mM) when compared to Tpmt
+/+ cultures (p,0.04). Interest-
ingly, Tpmt
+/2 but not Tpmt
2/2 astrocytes were significantly more
sensitive at 1.25 mM of TG than Tpmt
+/+ astrocytes (p=0.004);
and this finding was reflected in corresponding IC50 values. There
was a 2.9 fold reduction in IC50 in Tpmt
+/2 (3.5 mM TG) versus a
1.2 fold reduction in Tpmt
2/2 (8.6 mM TG) when compared
Tpmt
+/+ astrocytes (10.3 mM TG); and the Tpmt
+/2 and Tpmt
2/2
IC50 values were significantly different from Tpmt
+/+ (p,0.05)
(Fig. 3b). Studies have shown that genotoxicity (i.e. DNA strand
breaks) correlates with cytotoxicity after TG exposure [33,36].
Hence, we investigated whether the degree of TG-induced DNA
strand breaks was associated with the level of cytotoxicity in
primary astrocytes.
Comparison of the extent of DNA damage between
Tpmt
+/+, Tpmt
+/2, and Tpmt
2/2 primary astrocytes
To address the question of whether the level of TG-induced
cytotoxicity is correlated with DNA damage, we employed the
alkaline comet assay. This assay allows for the quantitation of
DNA damage [i.e. single strand breaks (SSBs), double strand
breaks (DSBs) and alkali labile sites] by using fluorescent
Figure 2. Characterization of Tpmt
+/+, Tpmt
+/2, and Tpmt
2/2 primary astrocyte cultures. (a) Micrograph image (2006) of primary astrocytes
showing high astrocyte purity determined by GFAP (green) and propidium iodide (red) fluorescent staining. (b) There was no significant difference in
growth rates between astrocyte cultures of each Tpmt genotype (p=0.89). (c) The level of Tpmt protein activity was significantly different between
the three Tpmt genotypes (p=0.018); and levels were comparable to Nalm6 and CEM control lymphoblastoid cell lines. Bars represent the means;
whiskers represent the standard deviation (6); * p,0.05.
doi:10.1371/journal.pone.0029163.g002
Tpmt Phenotypes in Astroglial Cells
PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e29163microscopy to visualize the extent of DNA migration from the
nucleus of individual cells embedded in agarose [37]. We exposed
astrocytes to 5 mM of TG for 72 hours. IC50 data was used to
select a dose that would allow us to capture damage in each
genotype. 72 hour time-point was selected to allow at least two
cell doublings for TG incorporation and to capture cell damage
prior to cell death. We observed a significant difference in DNA
damage between the three genotypes as measured by mean comet
tail moment. Both Tpmt
+/2 and Tpmt
2/2 astrocytes had a
significantly greater degree of DNA damage than Tpmt
+/+
astrocytes (mean comet tail moment=2.64, 1.26, and 0.4,
respectively; p=0.034) (Fig. 3c). In agreement with MTT studies,
Tpmt
+/2 astrocytes were more sensitive to TG, as evidenced by a
greater degree of DNA damage, than were Tpmt
2/2 astrocytes.
Although the difference in DNA damage between Tpmt
+/2 and
Tpmt
2/2 astrocytes was not significantly different (p=0.083).
Figure 3. Comparison of thioguanine phenotypes in primary astrocyte cultures of each Tpmt genotype. (a) Primary astrocytes of each
Tpmt genotype were exposed to thioguanine (TG) and cell viability was determined using the MTT assay. Tpmt
+/2 and Tpmt
2/2 astrocytes were
significantly more sensitive to TG (12.5–100 mM) than Tpmt
+/+ (p,0.04). (b) IC50 values were significantly different between the three genotypes
(p=0.027) and Tpmt
+/2 astrocytes were the most sensitive. (c) The alkaline comet assay was used to compare TG-induced DNA damage between
genotypes. Tpmt
+/2 and Tpmt
2/2 astrocytes had significantly higher mean comet tail moments than Tpmt
+/+ astrocytes (p=0.033). (d)
Immunoflourescence staining for cH2AX confirms IC50 and comet data. Tpmt
+/2 astrocytes had greater damage than Tpmt
+/+(p=0.03). Below are
representative images of cH2AX staining for control treated (left) and TG treated (right) astrocytes. cH2AX foci stained in green; nuclei stained in red
(Zeiss LSM 710 Laser Scanning Microscopes, 4006magnification). Bars represent the means; whiskers represent the standard deviation (6); * p,0.05.
doi:10.1371/journal.pone.0029163.g003
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genotypes of control treated astrocytes.
Studies have shown that the predominant DNA lesions caused
by TG are SSBs although some DSB lesions are formed [33].
Therefore, we then compared cH2AX (an established DSB
marker) foci staining after TG exposure to determine the extent of
the DNA lesions that are in the form of DSBs and whether this
damage is different between Tpmt genotypes. Astrocytes were
seeded on glass coverslips and exposed to either 0 or 5 mM of TG.
We found that Tpmt
+/2 astrocytes had the greatest degree of foci
staining (19.4%) compared to Tpmt
+/+ (9.3%), and Tpmt
2/2
(7.22%) (Fig. 3d). In agreement with comet data, Tpmt
+/2 was the
most sensitive genotype. There was a significant difference
between Tpmt
+/2 and Tpmt
+/+ (p=0.03) but no significant
difference was observed between Tpmt
2/2 and Tpmt
+/+ cells.
Comparison of thioguanine phenotypes between human
glioma cell lines with different Tpmt protein activities
To determine whether our findings could be recapitulated in
human cell lines, we used established human glioma cell lines as
model astroglia and conducted MTT and comet experiments. We
first identified cell lines with high and low Tpmt activity and
compared TG-induced cytotoxicity and DNA damage between
them. First, we measured Tpmt protein activity in four human
glioma cell lines (T98, A172, U87, and LN18) to identify a high and
low Tpmt expresser. We chose T98 (10.48unit/10
9 mg protein) and
A172 (6.15 unit/10
9 mg protein) as the high and low expressers,
respectively (Fig. 4a). We then subjectedT98 and A172 to the MTT
assay to measure TG-induced cytotoxicity. Both cell lines were
exposed to escalating concentrations of TG (0.15, 0.75, 1.5, 6.25,
12.5 and 25 mM) for five days. The cell viability was determined for
each concentration and these data were used to calculate IC50
values. As predicted by Tpmt activity and in agreement with MTT
studies performed in primary astrocytes, A172 had significantly
lower cell viabilities at each TG concentration as compared to T98
(p,0.05) (Fig. 4b). The higher TG sensitivity of A172 was also
reflected in the IC50 values. A172 displayed a 6.9 fold lower IC50
(1.2 mM) when compared to T98 (8.3 mM) (Fig. 4c).
Next, we employed the comet assay to compare DNA damage
between T98 and A172 after exposing cells to 3 mM TG for
72 hours. In agreement with primary astrocyte data, a low level of
Tpmt activity led to significantly more DNA damage compared to
high activity (mean comet tail moment: A172=1, T98=0.3;
p=0.02) (Fig. 4d). DNA damage in control treated cells was not
significantly different between the two cell lines.
Comparison of thioguanine phenotypes between
A172
mock and A172
Tpmt isogenic cell lines
To further validate our findings, TG phenotypes were
compared using isogenic cell lines. A172 was the lowest Tpmt
expresser, hence we over-expressed Tpmt in this cell line and
compared TG-induced cytotoxicity and DNA damage between
the mock transduced (A172
mock) and Tpmt transduced (A172
Tpmt)
cell lines. We performed growth rate studies and found that there
Figure 4. Assessment of Tpmt-associated phenotypes in model astroglial cell lines. Tpmt protein activity was measured in T98 and A172
glioma cell lines. (a) T98 displayed a significantly higher level of protein activity than A172 (p,0.05). (b) As observed in primary astrocyte cultures, low
Tpmt protein activity is associated with greater cytotoxicity as determined by the MTT assay; (c) and reflected in IC50 values. A172 had a significantly
more sensitive at all TG concentrations and lower IC50 than T98 (p,0.05). (d) The alkaline comet assay was used to compare TG-induced DNA
damage. A172 displayed a significantly greater degree of TG-induced DNA strand breaks than T98 (p=0.02) as measured by mean comet tail
moment. Bars represent the means; whiskers represent the standard deviation (6); * p,0.05; ** p,0.005.
doi:10.1371/journal.pone.0029163.g004
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Tpmt and
A172
mock (28.5 and 29.6 hours, respectively; p=0.38). The level
of Tpmt protein activity in A172
Tpmt was significantly higher as
compared to A172
mock (151.23 unit/10
9 mg protein versus 9.47
unit/10
9 mg protein, respectively; p,0.05) (Fig. 5a). When
A172
mock and A172
Tpmt were exposed to escalating concentrations
of TG for five days we found that A172
mock had significantly lower
cell viabilities at 0.75, 1.5, 6.25, 12.5 and 25 mMo fT Ga s
compared to A172
Tpmt (p,0.005) (Fig. 5b). These findings were
reflected in the A172
Tpmt IC50 value that was approximately two-
fold higher than A172
mock (3.9 mM versus 1.9 mM, respectively;
p,0.05)(Fig. 5c).
Next, we exposed A172
Tpmt and A172
mock to 5 mM of TG for
72 hours and compared the extent of DNA damage using the
comet assay. We selected 5 mM based on the IC50 value of
A172
Tpmt. As expected, A172
mock had a significantly greater
degree of DNA damage when compared to A172
Tpmt (mean
comet tail moment: A172
mock=0.7, A172
Tpmt=0.24; p=0.03)
(Fig. 5d). DNA damage in control treated cells was not significantly
different between the two cell lines (p=0.35). These data support
our findings observed in both the primary mouse astrocytes and
the glioma cell lines (T98 and wild-type A172) that when Tpmt
protein activity is low a greater degree of cytotoxicity and DNA
damage can occur after TG exposure.
Discussion
Tpmt is a cytoplasmic enzyme responsible for deactivating
thiopurine drugs and a low Tpmt phenotype can lead to life-
threatening hematological toxicities when thiopurines are given.
Indeed, chronic administration of thiopurines has been linked to
an increased risk of cancer including cancers of the brain
[8,15,17,22,24]. Unfortunately, not all patient populations that
are treated with thiopurines are evaluated for their Tpmt status
prior to initiating thiopurine therapy; hence, the importance of
Tpmt to thiopurine-associated cancer risk is not clear. This fact
coupled with the fact that Tpmt deficiency is relatively rare across
populations, makes it difficult to assess the importance of Tpmt
status to thiopurine therapy-related cancer risk. However, in a
report by Relling et al whether patients developed a brain tumor as
a late complication post-antileukemic therapy depended on their
Tpmt status [24]. In this report, patients who were determined to
be at high risk for treatment relapse received prophylactic cranial
irradiation concurrent with antimetabolite therapy; and those
patients with a low Tpmt had a surprisingly high incidence of
brain tumors as a late complication. Indeed, ionizing radiation in
itself is a risk factor for brain tumorigenesis. However, in this
report, patients with low Tpmt had a 42.9% incidence of brain
tumors compared to 15.8% for those with high Tpmt.
Astrocytomas are the most common brain tumor type that has
beenreported in patients after thiopurine therapy [8,15,22,24]. The
importance of Tpmt status to thiopurine-associated phenotypes in
astroglial cells has never been studied. We assessed Tpmt and TG
phenotypesinastroglialcellsusing primarymouseastrocytesofeach
Tpmt genotype and human glioma cells of different Tpmt
phenotypes. In this study we have shown that TG induces
cytotoxicity in a dose-dependent manner in astroglial cells; and
Figure 5. Comparison of Tpmt-associated phenotypes in A172 isogenic cells. Tpmt protein activity was measured in A172
mock and
A172
Tpmt cell lines. (a) Tpmt protein activity was significantly higher in A172
Tpmt (p,0.05); additionally, (b) A172
Tpmt showed a significantly higher
resistance to TG-induced toxicity when compared to A172
mock as determined by the MTT cell viability data (p,0.005) and (c) by IC50 values (p,0.05).
(d) The alkaline comet assay was used to compare TG-induced DNA damage. A172
mock displayed a significantly higher DNA damage than A172
Tpmt
(p=0.03) as measured by mean comet tail moment. Bars represent the means; whiskers represent the standard deviation (6). * p,0.05.
doi:10.1371/journal.pone.0029163.g005
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+/2 and Tpmt
2/2 astrocytes
and A172
mock) were significantly more sensitive. We also showed
that TG exposure induced more DNA damage in the form of SSBs
in astroglial cells with low Tpmt than in cells with high Tpmt. DNA
damage in the form of DSBs was significantly different between
astroglialcellswith lowandhighTpmt.SSBshavebeen showntobe
the primary DNA lesion induced by thiopurine drugs [33].
Interestingly, we found that low but not the complete absence of
Tpmt sensitized primary astrocytes to a higher degree of
cytotoxicity and genotoxicity (i.e. IC50, SSBs and DSBs) after
TG exposure. This discordance could possibly be explained by the
induction of a compensatory mechanism that deactivates thiopur-
ines with the complete loss of Tpmt. Another possible explanation
could be a defect in the mismatch repair (MMR) system’s ability to
recognize DNA-TG nucleotide lesions. The MMR system is
responsible for recognizing DNA mis-pairing caused by DNA-TG
nucleotides and the subsequent signaling for cell death
[38,39,40,41]. The latter possibility suggests that astroglial cells
with a defective Tpmt could have DNA lesions persisting in the
genome that could potentially lead to mutagenesis and cancer.
Indeed, some studies suggest that heterozygous children develop
brain tumors and other cancers more often than children with
mutant Tpmt. However, the frequency of heterozygous or mutant
Tpmt is very low making it is difficult to make any definitive
conclusions [24,42]. It would be interesting to investigate whether
Tpmt status influences the extent of TG nucleotide incorporation
into DNA and damage recognition by the MMR system as well as
whether ionizing irradiation alone or combined with thiopurines
results in similar findings.
In summary, chronic thiopurinetherapy has been associated with
the development of brain cancer and Tpmt status has been linkedto
this risk. We found that Tpmt is an important factor for thiopurine
drug-induced cytotoxicity and genotoxicity in astroglial cells. Even
though glioma cells can exhibit a number of genetic alternations
that could contribute to the phenotypes observed, our study shows
that Tpmt is indeed an important determinant of thiopurine
toxicity. Low Tpmt can increase the level of TG-induced genotoxic
damagein both normalandin neoplastic astroglialcells.Indeed, the
observations that glioma cells can have variable degrees of Tpmt
protein activity and that low protein activity can cause cells to be
moresensitive to TG poses the question of whether thiopurines may
potentially have a therapeutic role in low Tpmt expressing glial
tumors. In vitro studies have shown that thiopurine drugs are
associated with mutagenic events in a variety of cell lines [30,36]. It
is possible that the DNA damage caused by low Tpmt function can
ultimately contribute to transformative events over time. One study
found that Tpmt was not an important factor for cancer risk after
thiopurine therapy [42]; however in this study only Tpmt genotype
was determined which may have excluded patients with discor-
dance between Tpmt genotype and phenotype. Individuals who are
wild-type for Tpmt can display a wide variation in their Tpmt
phenotype [43]. Further studies are needed to understand the
importance of Tpmt in the brain when thiopurines are given.
Whether thesesfindings canbe replicated in vivoand whether factors
important to DNA repair mechanisms are responsible for the TG
phenotypes described in this study should also be investigated.
Materials and Methods
Animals
The Tpmt knockout mice were a generous gift of Dr. Mary
Relling (St. Jude Children’s Research Hospital) and the generation
of these mice has been described previously [35]. The Tpmt
+/2,
and Tpmt
2/2 mice were indistinguishable from Tpmt
+/+ mice by
appearance, life span, and organ histology (i.e. brain, liver, spleen,
intestine, thymus, and lymph nodes). Animals were maintained in
accordance to NIH guidelines for the care and use of laboratory
animals and were housed in an AAALAC accredited facility. The
University of Tennessee Health Science Center Institutional
Animal Care and Use Committee approved all animal procedures.
Primary astrocyte cultures and cell lines
Astrocyte cultures were established from 2–5 day old pups of
each Tpmt genotype. The DNA extracted from tails snips was used
to confirm Tpmt genotype. A dissecting microscope was used to
remove the meninges and hippocampus and the cortices were
mechanically dissociated. Subsequently, cultures were established
and maintained in Dulbecco’s modified Eagle’s medium/Ham’s F-
12 50/50 mix (Cellgro) supplemented with 10% fetal bovine
serum, 2 mM L-glutamine, 100 IU/ml penicillin, 100 mg/ml
streptomycin and 20 ng/ml epidermal growth factor (Millipore)
and grown in Primaria flasks, (BD biosciences). Cells were refed
with 20 ng/ml epidermal growth factor after three days of
incubation, and the media was changed after five days. At passage
2, three individual primary cultures of the same genotype were
pooled and seeded for experiments. Only cultures with greater
than 80% astrocyte purity as determined by GFAP immunohis-
tochemistry were included in experiments.
The T98 and A172 cell lines were obtained from the American
Type Culture Collection (Manassas, VA, USA). T98 was grown in
Minimum Essential Medium Eagle (Cellgro), supplemented with
10% fetal bovine serum, 2 mM L-glutamine, 0.1 mM nonessential
amino acids, 1 mM sodium pyruvate, 100 IU/ml penicillin, and
100 mg/ml streptomycin. A172 was grown in Dulbecco’s Modified
Eagle’s Medium (Cellgro), supplemented with 10% fetal bovine
serum, 2 mM L-glutamine, 100 IU/ml penicillin, and 100 mg/ml
streptomycin. All cell cultures were maintained at 37uCi na5 %
CO2 humidified atmosphere.
Lentiviral transduction
Human Tpmt cDNA was obtained by digesting pCMV6-Tpmt
plasmid (Origene) at BamHI and EcoRI sites. Tpmt cDNA was
then amplified by PCR, purified through agarose gel electropho-
resis, and subcloned into BamHI and EcoRI sites of pLenti-CMV-
pgk-puro vector (Viral vector core, UTHSC). The plenti-Tpmt-
pgk-puro and plenti-GFP-pgk-puro lentivial vectors were pro-
duced by packaging in 293T cells [44]. The lentiviral vectors were
used to transduce the A172 cell line in the presence of 6 mg/mL
polybrene (Sigma). Transduction efficiency was monitored by GFP
expression using fluorescent microscope. The mock- (A172
mock)
and Tpmt-transduced (A172
Tpmt) cell lines were seeded for
experiments at comparable passage numbers and Tpmt activity
was measured prior to the experiments.
Cell proliferation comparison
The doubling rates for primary astrocyte cultures were
determined and used as an index of cell proliferation. At passage
two, 75,000 cells/well were seeded in duplicate 6-well plates.
Every 24 hours the cells from one well of each plate were
harvested using 0.05% Trypsin-EDTA (GIBCO) and viable cells
were counted by trypan blue exclusion for four consecutive days.
Doubling rates were calculated using the following formula:
Doubling time (hours)=(T2-T1)/[log26(Log N-Log N0)]. Where,
T2=Harvesting time, T1=Initial time, N=Final cell concentra-
tion, and N0=Initial cell concentration. The mean doubling rate
was calculated from replicate experiments using two different
pooled cultures established on different days.
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Primary mouse astrocyte and human glioma cell lines were
sonicated using a probe sonicator (Masonix XL-2000 series) prior
to performing the Tpmt activity assay. The level of Tpmt activity
was determined using a pre-established non-chelated radiochem-
ical assay [26,34] with slight modifications. Tpmt activity was
quantitated by measuring the extent of conversion of 6-
mercaptopurine (Sigma) to radioactively labeled 6-methylmercap-
topurine with [14C] S-adenosyl-L-methionine (SAM) (Perkin-
Elmer). The protein concentration of each lysate was measured
prior to performing the assay and was used to calculate Tpmt
activity. The mean activities for each genotype were calculated
using data from triplicate inter-day studies of three separate pooled
cultures per Tpmt genotype.
MTT assay
Cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (Sigma). Briefly, 1000 cells were
seeded per well in 96-well plates. Plates were pre-coated with poly-
L-ornithine (Sigma) and Laminin (Invitrogen) for primary
astrocytes to facilitate cell attachment. A fifteen millimolar stock
solution of TG (Sigma) was prepared by dissolving TG in 0.1 N
NaOH. Cells were allowed to attach over night and TG or vehicle
control was added to the appropriate wells. After five days of drug
exposure, MTT was added and allowed to incubate for 3 hours.
Afterwards, the media was carefully aspirated and the purple
formazan crystals were dissolved in 100 ml DMSO (Fisher).
Absorbance was measured at wavelength of 570/690 nm using a
FLx800 fluorescence microplate reader (BioTek Instruments, Inc.).
Alkaline comet assay
Techniques used to perform the comet assay were adopted from
the laboratory of Dr. Peter Mckinnon (St. Jude Children’s
Research Hospital) [45]. Briefly, 50,000 primary astrocyte or
30,000 human astroglial cells were seeded in Primaria 24-well
plates (BD Biosciences) or in Falcon 24-well plates (BD
Biosciences), respectively. Cells were allowed to attach overnight
and then exposed to TG for three days. After three days of drug
treatment, cells were harvested and counted to prepare a 3610
5
cells/ml suspension in PBS. The cell suspension was mixed with
1.2% ultra-pure low melting point agarose (Invitrogen) and casted
onto chilled fully frosted glass slides (Fisher) pre-coated with 0.6%
agarose (Bio-Rad). The cells were then lysed for 1.5 hours at 4uC,
in lysis buffer (100 mM EDTA, 2.5 M NaCl, 10 mM Tris, 1.3%
triton X-100 and 3.3% DMSO). The slides were washed twice
with distilled water and incubated for 45 minutes at 4uCi n
electrophoresis buffer (1 mM EDTA, 50 mM NaOH and 1%
DMSO). Electrophoresis was conducted at 12 V and ,90 mA at
4uC for 25 minutes. Slides were incubated for one hour in
400 mM Tri-HCl neutralization buffer followed by a 20 minute
incubation in SYBR green I (Sigma). Images were captured using
a Nikon eclipse TE300 fluorescent microscope. All experiments
were replicated using two different sets of pooled cultures. The
extent of DNA damage was expressed as the comet tail moment
(the amount and distribution of DNA in the tail). The comet tail
moment was measured in a minimum of 60 cells using Cometscore
version 1.5 (Tri Tek corp).
Immunohistochemistry
Primary astrocytes were grown on poly-D-lysine chamber slides
(BD Biocoat) for GFAP staining (to confirm astrocyte purity) or on
glass coverslips and treated with 0 or 5 mM of TG for cH2AX
staining. Cells were fixed with 4% PFA/PBS for 10 minutes,
permeabilized with 0.5% Triton X-100/PBS for 5 minutes. Cells
werethen washedwith PBSand blocked with3% BSA/PBSfor one
hour. Cells were then immunostained with either anti-GFAP (1:500
in PBS, Sigma) for two hours or anti-cH2AX (1:1000 in 3%BSA,
Milipore) for one hour. Subsequently, cells were washed with PBS
and incubated for one hour with in Cy2-conjugated donkey anti-
mouse secondary antibody (Jackson ImmunoResearch, 1:250 in
PBS containing 2% donkey serum and 0.1% Triton X-100) for
GFAP or with donkey anti-mouse secondary antibody labeled with
Alexa 488 (In vitrogen, 1:800 in 3% BSA) for one hour. Finally,
vectashield mounting media (Vectorlabs) containing propidium
iodide was used to stain nuclei. GFAP slides were visualized and
images were captured using Nikon eclipse TE300 fluorescent
microscope.Imageswerecaptured for cH2AX stainedslides usinga
LSM-710 confocal microscope (Zeiss). Images were analyzed for
cH2AX foci by counting a minimum of 100 cells per genotype.
Cells containing fewer than five foci were excluded to normalize for
baseline staining observed in control treated cells. Cells with ‘‘pan-
staining’’ were considered to have more than 5 foci per cell. Hence,
the percent of cells with cH2AX foci staining represents the percent
of cells with greater than five foci per cell.
Statistical analysis
Differences in cytotoxicity and DNA damage among all three
groups were compared using Kruskal-Wallis analysis of ranks. Mann-
Whitney U test was used when only two groups were compared.
Significance was declared when p,0.05. All statistical analyses were
performed using SAS 9.2 (SAS Institute Inc., Cary, NC).
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